Table 1.
Clinical features of training set (n = 257) and verification set (n = 256).
| Verification set | Training set | p | SMD | |
|---|---|---|---|---|
| Number | 256 | 257 | ||
| Age = >45 (%) | 246 (96.0) | 240 (93.4) | 0.256 | 0.114 |
| Clinical stage (%) | ||||
| Stage I | 1 (0.4) | 2 (0.7) | 0.98 | 0.211 |
| Stage IA | 80 (30.9) | 81 (31.1) | ||
| Stage IB | 72 (26.8) | 70 (25.6) | ||
| Stage IC | 14 (5.5) | 9 (3.3) | ||
| Stage II | 16 (6.2) | 14 (5.9) | ||
| Stage IIA | 2 (1.1) | 2 (1.1) | ||
| Stage IIB | 6 (2.6) | 5 (2.2) | ||
| Stage III | 1 (0.4) | 1 (0.4) | ||
| Stage IIIA | 19 (7.7) | 15 (7.0) | ||
| Stage IIIB | 3 (1.1) | 3 (1.1) | ||
| Stage IIIC | 14 (5.5) | 16 (6.2) | ||
| Stage IIIC1 | 9 (3.7) | 11 (4.4) | ||
| Stage IIIC2 | 9 (3.7) | 11 (4.4) | ||
| Stage IV | 2 (0.7) | 2 (0.7) | ||
| Stage IVA | 0 (0.0) | 2 (1.1) | ||
| Stage IVB | 9 (3.7) | 12 (4.8) | ||
| Histological type (%) | ||||
| Endometrioid endometrial adenocarcinoma | 199 (76.8) | 189 (72.9) | 0.523 | 0.098 |
| Mixed serous and endometrioid | 11 (4.0) | 11 (4.0) | ||
| Serous endometrial adenocarcinoma | 47 (19.1) | 57 (23.1) | ||
| Histological grade (%) | ||||
| G1 | 51 (19.9) | 42 (16.5) | 0.408 | 0.146 |
| G2 | 53 (20.2) | 63 (24.5) | ||
| G3 | 149 (58.5) | 144 (56.4) | ||
| High grade | 4 (1.5) | 7 (2.6) | ||
| Menopause status (%) | ||||
| Indeterminate | 9 (3.3) | 8 (2.9) | 0.368 | 0.2 |
| Peri | 11 (4.0) | 6 (2.2) | ||
| Post | 221 (81.2) | 221 (82.1) | ||
| Pre | 15 (5.5) | 20 (7.3) | ||
| OS = DEAD (%) | 45 (16.5) | 46 (16.8) | 1 | 0.008 |
Menopause status: Indeterminate: neither pre nor postmenopausal; Peri: 6 to 12 months since last menstrual period; Post: prior bilateral ovariectomy OR > 12 or since LMP with no prior hysterectomy; Pre: <6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement.